Navigation Links
Ambit Biosciences Initiates Two Phase I Clinical Trials
Date:12/20/2010

SAN DIEGO, Dec. 20, 2010 /PRNewswire/ -- Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.

The Phase I trial for AC430 is a two part, placebo-controlled, single ascending, and multiple ascending dose trial in healthy volunteers.  AC430 will be administered orally once-daily and doses escalated until a maximum tolerated or maximum feasible dose is established.  In addition to evaluating the safety, tolerability, and pharmacokinetics of AC430, the study will also assess cytokine signal transduction.  

The Phase I trial for AC480 is a multi-center, dose escalation study with AC480 administered by intravenous infusion on days one and two of a 21 day cycle, either alone or in combination with docetaxel.  The trial will assess safety, pharmacokinetics and anti-tumor activity of AC480 in patients with advanced solid tumors.

"The initiations of these studies are important milestones," said Alan Lewis, President and CEO Ambit Biosciences. "AC430 has demonstrated convincing efficacy in pre-clinical models of autoimmune and inflammatory diseases, and AC480 IV was developed to assess whether pulsatile doses of a pan-HER inhibitor administered in combination with a taxane such as docetaxal would produce synergistic anti-tumor activity."

About AC430AC430 was specifically developed to be a best-in-class JAK2 inhibitor.  In preclinical studies, AC430 has exhibited potency against JAK2 in cell-based models that is at least equivalent, and in most cases superior to, competing JAK2 inhibitors, and also has excellent oral pharmacokinetic properties.  In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.  JAK2 has been implicated as a target for therapy in both oncology and autoimmune disease.

About AC480AC480 is a small molecule kinase inhibitor that selectively inhibits the HER family of receptors, HER1, HER2, HER3 and HER4.  Excessive HER signaling has been associated with the development of a wide variety of types of solid tumors, including those found in lung, breast, head and neck and brain cancers.  Currently marketed HER inhibitors inhibit only one or two of the HER family members and a pan-HER inhibitor that inhibits all of the HER receptors may be effective in more cancer types.  Published data with oral HER inhibitors administered in combination with taxanes, such as docetaxel, demonstrate activity in clinical studies and these clinical data are supported by preclinical data demonstrating that combining HER inhibitors with taxanes produces synergistic anti-tumor activity.  An intravenous formulation of a pan-HER inhibitor such AC480 enables high pulsatile doses to be administered in combination with taxanes.

About Ambit BiosciencesAmbit Biosciences Corporation is a biotechnology company engaged in discovering, developing and commercializing targeted small molecule therapeutics for the treatment of cancer.

Ambit contacts:Alan Fuhrman, Chief Financial Officer, Ambit Biosciences (858) 334-2133, afuhrman@ambitbio.com

Christopher Morl, Chief Operating Officer, Ambit Biosciences (858) 334-2134, cmorl@ambitbio.comContact:Carol RuthThe Ruth Group(646) 536-7004cruth@theruthgroup.com
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Strengthens Board of Directors and Executive Team
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
4. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
5. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
6. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
7. Cell Biosciences Announces US Patent Issuance
8. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
9. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
10. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
(Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... personal financial planning to families and business owners in North Central West Virginia, ... help provide services to differently abled residents in the region. , The Stepping ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier provider ... certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, South ... law has been degraded. The PSC.1 standard was created to protect fundamental freedoms ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a premier ... private equity firm, has invested $3.35 million in the company. , “We ... Capital offers the smart money, speed to market and accountability we had been ...
Breaking Medicine News(10 mins):